Phillips Medisize

Phillips Medisize employee working in the pharmaceutical technology service lab, while we can see another employee walk past outside the window. Through the window, another corridor shows another employee in a neighbouring room.

INHALATION AND NASAL EXPERTISE

The 2025 Vectura acquisition expanded our capabilities. Today, we specialize in innovative inhaled drug development, leveraging more than 25 years of experience to help bring your medicines to market. Our combination of formulation science, device technology and inhaled development expertise has contributed to the success of 13 inhaled medicines launched by our partners and licensees. In 2020 alone, these products were used by 10 million patients worldwide.1

Our expertise spans small molecules, biologics, complex combinations and generic products for pMDI, DPI, nasal inhaler and nebulization devices. We invite you to explore more about our proven inhalation services:

A Phillips Medisize employee working in a pharmaceutical clean room, wearing a lab coat, gloves and protective glasses, he is working on developing inhalation products
Inhalation Product Development
Learn more
A close-up image of a Phillips Medisize scientist, working on formulation for an inhalation device. The scientist holds a glass bottle wearing gloves.
Inhalation Formulation Expertise
Learn more
An image of the FOX Vibrating Mesh Nebulizer being tested as part of the pharmaceutical analysis process
Inhalation Pharmaceutical Analysis
Learn more
A close up image of a roll of blister packaging feeding through a machine to be prepared to be inserted into a dry powder inhaler
Bespoke Inhalation Device Design
Learn more
An image of a scientist in a lab coat and wearing PPE while working on machinery to develop and produce inhalation products
Inhalation Clinical Trial Production and Supply
Learn more

Our Track Record

Fluticasone Propionate and SalmeterolHikma
Formulation + Device + Development
flutiform™ 2
Mundipharma, Kyorin
Formulation + Device + Development
flutiform™ k-haler™ 2
Mundipharma, Kyorin
Formulation + Device + Development
Airbufo™ Forspiro™ 3
Sandoz
Formulation + Device + Development
AirFluSal™ Forspiro™ 3
Sandoz
Formulation + Device + Development
Breelib™4Bayer
Formulation + Device + Development
Seebri™ Breezhaler™ 3
Novartis
Formulation
Ultibro™ Breezhaler™ 3
Novartis
Formulation
Enerzair™ Breezhaler™ 3
Novartis
Formulation
Relvar™ Ellipta™ 5
GSK
Formulation
Anoro™ Ellipta™ 5
GSK
Formulation
Incruse™ Ellipta™ 5
GSK
Formulation
Trelegy™ Ellipta™ 5
GSK
Formulation

1. Evaluate Pharma; internal estimates. 2. flutiform™ is a registered trademark of Jagotec AG, a Vectura company. K-haler™ is a registered trademark of Mundipharma AG. 3. AirFluSal™, Airbufo™, Forspiro™, Seebri™, Ultibro™, Enerzair™ and Breezhaler™ are registered trademarks of Novartis AG. 4. Breelib™ is a registered trademark of Bayer Intellectual Property GmbH. 5. Registered trademarks of Glaxo Group Ltd. Formulation technology license, product not developed by Vectura.

PLATFORM PRODUCTS

At Phillips Medisize, our customizable platform products help you accelerate development timelines, minimize risk and optimize costs. You can rely on our world class engineering team to tailor solutions to your needs. By investing in advanced technologies, we bring award-winning approaches to the toughest engineering challenges – always aligning our work with your objectives.:

An image of a scientist in a lab coat working on testing a Dry Powder Inhaler
Dry Powder Inhalers (DPI)
Our dry powder inhalers build on the commercially validated AirFluSal™ GyroHaler™ platform and offer a variety of user interfaces and payload volumes, giving you confidence in performance and a proven regulatory track record.
Learn more
An image of a scientist working on the development of the FOX Vibrating Mesh Nebulizer
FOX™ Vibrating Mesh Nebulizer
The FOX™ is a compact, handheld, breath‑activated, battery‑powered inhalation system that uses vibrating‑mesh technology to deliver nebulized liquid drugs with high, consistent performance. The device is CE‑marked and has a 510(k) premarket notification for marketing in the US.
Learn more

Featured Resources

Publication
FOX™ Vibrating Mesh Nebulizer from Phillips Medisize
ODD: Integrating Phillips Medisize and Vectura’s Operations
In this interview, Phillips Medisize’s Charlie Schumacher and Sandy Munro discuss the company’s progress on its integration of Vectura. Learn more.
Publications
OnDrug Delivery July 2025 cover.
ODD: Phillips Medisize Grows its Capabilities with Vectura
In this exclusive interview with ONdrugDelivery’s Guy Furness, Brian Thompson and Dave Thoreson of Phillips Medisize discuss the company’s expanded capabilities as a result of its recent acquisition of Vectura. Learn more.
Publications
OIC
PMPS: Elevate Your Molecule
Phillips Medisize’s 2025 acquisition of Vectura expanded its offerings to include inhaled drug development for small molecules, biologics and complex combinations for both novel and generic products. Learn more.

Connect with One of Our Team Members to Begin Your Journey Today

CONTACT US